Entry into the recovery business through the acquisition of VENEX
First written in FY2023-Q2. 18 of 21 entries say "Advanced", first in FY2023-Q2. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「Revenue was ¥3,533 million, up 9.3% year on year, as Standard Dry Plus, the flagship brand, Recovery Cool Plus, a renewal of the long-selling Comfort Cool, and the entry-level Comfort Poncho steadily increased offline sales, including at department stores.」
The recovery business increased sales by expanding offline sales at department stores and other outlets in addition to online sales. However, advertising expenses and organizational strengthening, including recruitment, resulted in an operating loss of ¥165 million. - FY2026-H1AdvancedAnnual report
「Revenue steadily increased in both online sales and offline sales through department stores and other outlets, reaching a record ¥1,797 million for a mid-year consolidated accounting period, up 18.6% year on year.」
The recovery business operated through VENEX expanded offline sales through department stores and other outlets in addition to online sales, resulting in record first-half revenue. However, advertising and promotional expenses and organizational strengthening, including recruitment, resulted in an operating loss of ¥63 million. - FY2025AdvancedAnnual report
「Revenue was ¥3,233 million, substantially exceeding the initial plan and up 60.0% from the previous fiscal year, driven by the core Standard Dry Plus product and solid growth in seasonal products and entry-level models. The strengthening of supply chain management, covering the entire process from yarn production through fabric manufacturing and sewing, also progressed as planned, further strengthening the foundation for revenue growth.」
Following the acquisition of VENEX, the recovery business generated revenue of ¥3,233 million, up 60.0% from the previous fiscal year, while supply chain strengthening progressed as planned. - FY2025-H1AdvancedAnnual report
「Revenue increased substantially, partly due to the effect of actively implementing television commercials and digital marketing initiatives, reaching ¥1,515 million, the highest half-year revenue on record, up 68.6% year on year. Operating profit also increased steadily to ¥183 million, up 21.3% year on year.」
The recovery business operated through VENEX generated first-half revenue of ¥1,515 million and operating profit of ¥183 million through television commercials and digital marketing, exceeding the year-earlier period on both measures. Revenue reached a record high for a half-year period. - FY2024-Q3AdvancedAnnual report
「Revenue reached a third-quarter record of ¥1,337 million, as group synergies were realized through ongoing supply chain management initiatives and the development of new sales channels. The company appointed Ayako Imoto as its new brand ambassador in March 2024 and strengthened advertising investment to increase brand awareness, resulting in a substantial increase in traffic to its own website.」
In the recovery business, the company strengthened its supply chain, developed new sales channels and appointed a brand ambassador. Third-quarter revenue reached a record ¥1,337 million, while operating profit was ¥163 million. - FY2024-Q2AdvancedAnnual report
「Revenue reached a record ¥899 million, driven by strengthened supply chain management, the establishment of higher production capacity and the realization of group synergies in developing new sales channels. Operating profit also reached a record ¥151 million.」
In the recovery business, revenue and operating profit reached record highs of ¥899 million and ¥151 million, respectively, through supply chain strengthening, increased production capacity and the development of new sales channels. - FY2024-Q1AdvancedAnnual report
「Revenue from the recovery business performed strongly, reaching ¥340 million, as supply chain management was strengthened, production capacity was expanded, and group synergies were realized in marketing and new product development.」
In the recovery business following the acquisition of VENEX, the company strengthened the supply chain, built a higher production capacity and pursued group synergies in marketing and new product development, recording first-quarter revenue of ¥340 million and operating profit of ¥15 million. - FY2023AdvancedAnnual report
「At a meeting of the Board of Directors held on 17 January 2023, the company resolved to acquire all shares of VENEX and make it a subsidiary, and entered into a share transfer agreement on the same date. The acquisition of the shares was completed on 31 January 2023.」
The acquisition of VENEX was completed, and it was incorporated into consolidated results from January 2023. The company is strengthening marketing and e-commerce sales and expanding into the recovery business. - FY2023-Q3AdvancedAnnual report
「株式会社ベネクス was acquired during the second quarter consolidated accounting period and included in the scope of consolidation. The deemed acquisition date was 31 December 2022, and its income statement has been consolidated from the third quarter consolidated accounting period.」
Following the acquisition of all shares in VENEX, consolidation of its income statement began in the consolidated accounting period from the third quarter, marking the start of the recovery business's integration into consolidated results. - FY2023-Q2AdvancedAnnual report
「At a meeting of the Board of Directors held on 17 January 2023, the company resolved to acquire all shares of VENEX and make it a subsidiary, and entered into a share transfer agreement on the same date. The acquisition of the shares was completed on 31 January 2023.」
VENEX, which develops, manufactures, sells and conducts research and development on recovery wear, was made a wholly owned subsidiary. The objectives are to strengthen marketing and e-commerce sales, acquire branding and R&D capabilities in the recovery business, and pursue growth centered on the anti-aging business.